Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey (CROSBI ID 176180)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Burton, B.K. ; Guffon, N. ; Roberts, J. ; van der Ploeg, A.T. ; Jones, S.A. ; on behalf of the HOS investigators: Guelbert, N. ... ; Barić, Ivo ; Barišić, Ingeborg ; ... ; Ibrahim, J. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey // Molecular genetics and metabolism, 101 (2010), 2/3; 123-129. doi: 10.1016/j.ymgme.2010.06.011

Podaci o odgovornosti

Burton, B.K. ; Guffon, N. ; Roberts, J. ; van der Ploeg, A.T. ; Jones, S.A. ; on behalf of the HOS investigators: Guelbert, N. ... ; Barić, Ivo ; Barišić, Ingeborg ; ... ; Ibrahim, J.

engleski

Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey

Objestive waa to use our experience with patients in the observational database HOS - the Hunter Outcome Survey - to evaluate the feasibility of home infusions of idursulfase for patients with mucopolysaccharidosis type II (MPS II). Data were collected on or before 16 October 2009. Of 421 patients receiving idursulfase, 92 (21.9%) had received infusions at home or in an alternative, approved non-hospital environment. Information in HOS relating to the transition to home therapy was analyzed. Patients started home therapy after a median of 9.0months of idursulfase. Most were aged 5-11years at transfer (45.7% ; median age, 8.0years), but many (19.6%) were <5years of age. Patients had disease manifestations typical of the wider population ; over one- third had cognitive impairment, in some cases severe. Illness was the most frequent cause of missed home infusions. Six patients stopped home therapy ; four subsequently resumed home infusions. Five infusion-related reactions occurred in 2 of the 59 patients who had received home therapy for at least 12months. Reactions were classified as mild-to-moderate. All reactions that occurred at home were readily managed at home. Providing appropriate factors are considered, it should be feasible for patients with MPS II, including those who are severely affected, to receive infusions at home.

Hunter syndrome; mucopolysaccharidoses; Infusion; home therapy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

101 (2/3)

2010.

123-129

objavljeno

1096-7192

10.1016/j.ymgme.2010.06.011

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost